Thursday, July 19, 2012

FDA accepts NDA filing for KYNAMRO to treat HoFH...


Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc., announced,  that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for KYNAMRO(mipomersen sodium) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).....

No comments:

Post a Comment